"CRB-701: Promising Results in First-in-Human Study for Nectin-4 Positive Tumors"
Corbus Pharmaceuticals presented encouraging safety and efficacy data for CRB-701 (SYS6002), a next-generation antibody drug conjugate targeting nectin-4 positive tumors, at the 2024 ASCO GU Symposium. The Phase 1 study in China showed a 43% overall response rate and 71% disease control rate at predicted therapeutically relevant doses, with no dose-limiting toxicities observed up to 3.6 mg/kg. The drug demonstrated a differentiated pharmacokinetic profile and a safety profile devoid of peripheral neuropathy and skin rash, suggesting potential benefits for metastatic urothelial cancer and other nectin-4 positive solid tumors. Dose escalation and expansion are ongoing, with plans to commence a clinical study in the US in Q1 2024.
